- Conditions
- Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD), Metabolic Associated-dysfunction Steatohepatitis (MASH)
- Interventions
- Standard of care acceptance-based behavioral weight loss program, Occupational therapy dietary and lifestyle modifications
- Behavioral
- Lead sponsor
- Grand Valley State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Wyoming, Michigan
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, Obesity
- Interventions
- Metabolic surgery, Incretin-Based Therapy
- Procedure · Drug
- Lead sponsor
- Ali Aminian
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Indianapolis, Indiana • Rochester, Minnesota + 1 more
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, NAFLD - Non-Alcoholic Fatty Liver Disease
- Interventions
- Verasonics NXT Data Acquisition System, Philips EPIQ Elite, EchoSense FibroScan, Philips 3T Ingenia Elition
- Device
- Lead sponsor
- ContextVision AB
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Type 2 Diabetes, Prediabetes, Liver Disease
- Interventions
- Behavioral Treatment
- Device
- Lead sponsor
- SIPPA Solutions INC
- Industry
- Eligibility
- 22 Years to 65 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Jamaica, New York
- Conditions
- Food Insecurity
- Interventions
- Food Security Screening & Referral Program
- Behavioral
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- La Jolla, California • San Diego, California
- Conditions
- Liver Fibrosis Due to NASH, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Alcohol Liver Disease
- Interventions
- Not listed
- Lead sponsor
- Fibronostics USA, Inc
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 100 participants
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Lady Lake, Florida
- Conditions
- Metabolic Associated Fatty Liver Disease, Metabolic Associated Steatotic Liver Disease, Cirrhosis, Liver, NASH, Liver Fibrosis, Liver Fat, Liver Steatoses, Liver Inflammation
- Interventions
- Not listed
- Lead sponsor
- Foundation for the National Institutes of Health
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 400 participants
- Timeline
- 2025 – 2026
- U.S. locations
- 4
- States / cities
- Miami, Florida • Columbus, Ohio • Bellaire, Texas + 1 more
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Obesity, Overweight (BMI > 25)
- Interventions
- bis-octanoyl (R)-1,3-butanediol (C8 ketone di-ester), Placebo
- Drug · Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 25 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Steatotic Liver Disease of Mixed Origin (MetALD)
- Interventions
- Brief motivational interviewing with personalized feedback, Brief motivational interviewing with standard health information
- Behavioral
- Lead sponsor
- Brown University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis, Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-alcoholic Fatty Liver Disease (NAFLD)
- Interventions
- Miricorilant
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, NAFLD, Metabolic Dysfunction-associated Steatotic Liver Disease, Metabolic Dysfunction-associated Steatohepatitis
- Interventions
- Efinopegdutide, Placebo
- Combination Product
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 33
- States / cities
- Chandler, Arizona • Flagstaff, Arizona • Peoria, Arizona + 27 more
- Conditions
- Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Interventions
- ALN-PNP, Placebo (PB)
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 172 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 6
- States / cities
- Glendale, California • Los Angeles, California • Miami, Florida + 2 more
- Conditions
- Hyperoxaluria, Nonalcoholic Fatty Liver Disease, Kidney Stone
- Interventions
- BMN 255, Placebo
- Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Chula Vista, California • Chula Vista Isles, Florida + 4 more
- Conditions
- Metabolic-dysfunction-associated Fatty Liver Disease (MAFLD)
- Interventions
- Vibration-controlled transient elastography
- Device
- Lead sponsor
- William Jennings Bryan Dorn VA Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Columbia, South Carolina
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Cirrhosis
- Interventions
- AI-Enabled Identification (EchoNet-Liver)
- Other
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Palo Alto, California • Pleasanton, California + 1 more
- Conditions
- Type 2 Diabetes Mellitus, Impaired Glucose Tolerance, Non-Alcoholic Fatty Liver Disease, Obesity, Childhood
- Interventions
- Semaglutide Pen Injector, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 10 Years to 21 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease, Liver Disease
- Interventions
- Efinopegdutide
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 36
- States / cities
- Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 27 more
- Conditions
- MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Fatty Liver Disease, Nonalcoholic
- Interventions
- Thermoacoustic Enhanced Ultrasound
- Device
- Lead sponsor
- Endra Lifesciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease
- Interventions
- Tirzepatide, Retatrutide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 141
- States / cities
- Tuscaloosa, Alabama • Chandler, Arizona • Gilbert, Arizona + 122 more
- Conditions
- Non-Alcoholic Fatty Liver Disease, Steatosis of Liver, Metabolic Dysfunction-Associated Steatotic Liver Disease
- Interventions
- STIRRED
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4,704 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Obesity, Liver Diseases, Liver Fibrosis, Liver Fat, Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, MASLD, MASH, Weight Loss, Insulin Resistance, Insulin Sensitivity, Insulin Sensitivity/Resistance, Metabolic Disease, Diabetes, Diabetes Mellitus, Type 2, NASH With Fibrosis, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non-alcoholic Steatohepatitis
- Interventions
- ESG + lifestyle modification, Lifestyle modification
- Device · Behavioral
- Lead sponsor
- Pichamol Jirapinyo, MD, MPH
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Morgantown, West Virginia
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Non-alcoholic Fatty Liver Disease (NAFLD)
- Interventions
- Miricorilant
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Metabolic-dysfunction Associated Liver Disease (MASLD)
- Interventions
- Healthy Liver/Hígado Sano program, Usual Care
- Behavioral
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease
- Interventions
- Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)
- Diagnostic Test
- Lead sponsor
- PharmaNest, Inc
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 1,578 participants
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Richmond, Virginia